Finanzen von Alto Neuroscience Inc (ANRO)ANROAlto Neuroscience Inc

Evaluating the bottom line, Alto Neuroscience Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -49.17%, provide a clear picture of how effectively ANRO converts its operational activities into shareholder value.

In the context of the broader market, ANRO competes directly with industry leaders such as KURA and JBIO. With a market capitalization of $993.22M, it holds a leading position in the sector. When comparing efficiency, ANRO's gross margin of N/A stands against KURA's 98.84% and JBIO's N/A. Such benchmarking helps identify whether Alto Neuroscience Inc is trading at a premium or discount relative to its financial performance.

The company has reported consistent losses, with a net income of -$27.6 million in Q2 2026 and an EPS of -0.65. The current ratio remains strong at 14.85, indicating good short-term financial health despite ongoing losses.